JP2021036915A5 - - Google Patents

Download PDF

Info

Publication number
JP2021036915A5
JP2021036915A5 JP2020200805A JP2020200805A JP2021036915A5 JP 2021036915 A5 JP2021036915 A5 JP 2021036915A5 JP 2020200805 A JP2020200805 A JP 2020200805A JP 2020200805 A JP2020200805 A JP 2020200805A JP 2021036915 A5 JP2021036915 A5 JP 2021036915A5
Authority
JP
Japan
Prior art keywords
cells
aliquot
domain peptide
test
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020200805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021036915A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021036915A publication Critical patent/JP2021036915A/ja
Publication of JP2021036915A5 publication Critical patent/JP2021036915A5/ja
Withdrawn legal-status Critical Current

Links

JP2020200805A 2015-04-27 2020-12-03 ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法 Withdrawn JP2021036915A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562153475P 2015-04-27 2015-04-27
US62/153,475 2015-04-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017555779A Division JP6814745B2 (ja) 2015-04-27 2016-04-27 ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021036915A JP2021036915A (ja) 2021-03-11
JP2021036915A5 true JP2021036915A5 (cg-RX-API-DMAC7.html) 2021-11-11

Family

ID=57198812

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017555779A Active JP6814745B2 (ja) 2015-04-27 2016-04-27 ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法
JP2017555780A Active JP6802185B2 (ja) 2015-04-27 2016-04-27 ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術
JP2020200805A Withdrawn JP2021036915A (ja) 2015-04-27 2020-12-03 ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2017555779A Active JP6814745B2 (ja) 2015-04-27 2016-04-27 ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法
JP2017555780A Active JP6802185B2 (ja) 2015-04-27 2016-04-27 ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術

Country Status (6)

Country Link
US (4) US20180120297A1 (cg-RX-API-DMAC7.html)
EP (2) EP3288964B1 (cg-RX-API-DMAC7.html)
JP (3) JP6814745B2 (cg-RX-API-DMAC7.html)
AU (2) AU2016255749B2 (cg-RX-API-DMAC7.html)
CA (1) CA2983022C (cg-RX-API-DMAC7.html)
WO (2) WO2016176288A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016255749B2 (en) 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
WO2020060975A1 (en) * 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3931563A4 (en) * 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
WO2025212653A1 (en) * 2024-04-01 2025-10-09 Dana-Farber Cancer Institute, Inc. Methods including bh3 profiling of car t cells

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU705563B2 (en) 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
WO1997015831A1 (en) * 1995-10-24 1997-05-01 Sangstat Medical Corporation Anti alpha-galactosyl screening technique
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2001012661A2 (en) 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
WO2003040168A2 (en) * 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
EP1455819A1 (en) * 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1608969A4 (en) * 2003-03-19 2007-06-06 Alfa Wassermann Inc SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) * 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
US20070027175A1 (en) 2005-07-27 2007-02-01 Shaughnessy John Jr Antineoplastic activities of ellipticine and its derivatives
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Hccr-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) * 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
MX2011013385A (es) * 2009-06-11 2012-05-29 Minerva Biotechnologies Corp Metodos para cultivar celulas madre y celulas progenitoras.
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) * 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
WO2013170176A2 (en) * 2012-05-10 2013-11-14 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
WO2013188978A1 (en) 2012-06-20 2013-12-27 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
WO2014047342A1 (en) * 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
JP6327662B2 (ja) * 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
AU2016255749B2 (en) 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
US11092602B2 (en) 2015-07-06 2021-08-17 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
EP3931563A4 (en) 2019-02-26 2022-12-21 Dana-Farber Cancer Institute, Inc. BH3 DYNAMIC PROFILING FOR LIVING CELL IMAGING

Similar Documents

Publication Publication Date Title
JP2018520638A5 (cg-RX-API-DMAC7.html)
Mao et al. Folding of the mitochondrial proton adenosine triphosphatase proteolipid channel in phospholipid vesicles
Korner et al. Solubility of albumin in alcohol after precipitation by trichloroacetic acid: a simplified procedure for separation of albumin
Yamamoto et al. Analysis of the structure and function of EMRE in a yeast expression system
JP6663852B2 (ja) Bh3プロファイリングの方法
JP2021036915A (ja) ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法
Zingsheim et al. Electron microscopic methods in membrane biology
Asghar et al. Histochemical localization of glutathione in tissues.
US20070185074A1 (en) Synthetic molecules that specifically react with target sequences
Bismuto et al. Unfolding pathway of myoglobin. Evidence for a multistate process
Edwards et al. Distribution of transmembrane polypeptides in freeze fracture
Mishra et al. A chemical tool for blue light-inducible proximity photo-crosslinking in live cells
Berk Regulatable Fatty Acid Transport Mechanisms are Central to the Pathophysiology of Obesity, Fatty Liver, & Metabolic Syndrome
CN108267579A (zh) 稳定保存稀释液、抗核抗体检测试剂及其制备方法和应用
Nakamura et al. Derivatization of compounds at the origin of thin-layer plates with fluorescamine
Grodsky et al. Effect of modification of insulin on specific binding in insulin-resistant sera
Oshima et al. Recognition of exterior protein surfaces using artificial ligands based on calixarenes, crown ethers, and tetraphenylporphyrins
Ghang et al. Anionic deep cavitands enable the adhesion of unmodified proteins at a membrane bilayer
US20150080248A1 (en) Methods for isolating proteins
CA2259413A1 (en) Methods for determining the presence of brain protein s-100
Faletrov et al. Interaction of nitrobenzoxadiazole derivatives of piperazine and aniline with bovine serum albumine in silico and in vitro
Azmi et al. Introduction of cell‐selectivity in bovine cathelicidin BMAP‐28 by exchanging heptadic isoleucine with the adjacent proline at a non‐heptadic position
CN120040599A (zh) 一种分离纯化过氧化物酶体的方法
Kordyukova et al. Mass spectrometric approaches to study enveloped viruses: new possibilities for structural biology and prophylactic medicine
Say et al. Investigation of photosensitively bioconjugated targeted quantum dots for the labeling of Cu/Zn superoxide dismutase in fixed cells and tissue sections